SEC Comment Letter for CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — Oct 22, 2019
CervoMed Inc. (CRVO) (CIK 0001053691)
Date: Oct. 22, 2019 · CIK: 0001053691 · Accession: 0000000000-19-014765
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234234
Letter
October 22, 2019 David G. Kalergis Chief Executive Officer Diffusion Pharmaceuticals Inc. 1317 Carlton Avenue, Suite 200 Charlottesville, VA 22902 Re:Diffusion Pharmaceuticals Inc. Registration Statement on Form S-1 Filed October 16, 2019 File No. 333-234234 Dear Mr. Kalergis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David S. Rosenthal, Esq.
Show Raw Text
October 22, 2019
David G. Kalergis
Chief Executive Officer
Diffusion Pharmaceuticals Inc.
1317 Carlton Avenue, Suite 200
Charlottesville, VA 22902
Re:Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-1
Filed October 16, 2019
File No. 333-234234
Dear Mr. Kalergis:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David S. Rosenthal, Esq.